Evidence map›Paper›PMID 31172332›Full record

ArticleInternational journal of clinical oncology2019

Treatment-associated outcomes of patients with primary ocular adnexal MALT lymphoma after accurate diagnosis.

Yuya Masuda, Kazuto Takeuchi, Toshio Kodama, Tomoaki Fujisaki, Yoshitaka Imaizumi, Eiichi Otsuka, Shuji Ozaki, Shinji Hasebe, Yoshihiro Yakushijin

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuya MasudaDepartment of Clinical Oncology, Ehime University School of Medicine, Ehime, Japan.
Kazuto TakeuchiCancer Center, Ehime University Hospital, Toon, Japan.
Toshio KodamaDepartment of Ophthalmology, Matsuyama Red Cross Hospital, Ehime, Japan.
Tomoaki FujisakiDepartment of Hematology, Matsuyama Red Cross Hospital, Matsuyama, Japan.
Yoshitaka ImaizumiDepartment of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Eiichi OtsukaDepartment of Hematology, Oita Prefectural Hospital, Oita, Japan.
Shuji OzakiDepartment of Hematology, Tokushima Prefectural Central Hospital, Tokushima, Japan.
Shinji HasebeDepartment of Clinical Oncology, Ehime University Graduate School of Medicine, Tohon-shi, Shitsukawa Ehime, 7910295, Japan.
Yoshihiro YakushijinDepartment of Clinical Oncology, Ehime University Graduate School of Medicine, Tohon-shi, Shitsukawa Ehime, 7910295, Japan. yoshiyak@m.ehime-u.ac.jp.ORCID http://orcid.org/0000-0001-6001-746X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDifferentiation between primary ocular adnexal mucosa-associated lymphoid tissue (POA-MALT) lymphoma and reactive lymphoid hyperplasias sometimes may be difficult. We have examined the treatment-associated mortality of POA-MALT lymphoma after confirmed diagnosis and evaluated their proper treatments. PATIENTS AND

methodsFrom 1991 through 2016, cases of POA-MALT lymphoma were retrospectively analyzed based on their pathological and molecular/immunological diagnoses.

resultsA total of 78 cases with POA-MALT lymphoma with a median age of 66 years were analyzed over median/mean observations of 6.4/7.1 years. Forty-four patients (56%) were diagnosed with IgH gene clonality and 10 patients (13%) were diagnosed with flow cytometric analysis in addition to the pathological decision. The rest (24 patients, 31%) were diagnosed employing pathological decisions of hemato-pathologists and clinical decisions. All patients, except cases of watchful waiting, achieved complete remission. After initial treatment, 68 patients (87%) presented disease-free during the observation period. As treatment, a radiotherapy-based strategy was followed with 15 patients (19%, group A). Immuno-chemotherapy was administered to 24 patients (31%, B). Surgical extraction only was selected for 36 patients (46%, C). Watchful waiting was selected with three patients (4%). Recurrence after the initial treatment was found in one patient (7%) out of A, in three patients (13%) out of B, and in six patients (17%) out of C, respectively. Progression-free survivals at 5 and 10 years were 100 and 100% in A, 95 and 75% in B, and 88 and 81% in C, respectively. The recurrence rates between the patients who were diagnosed with only pathological decision (n = 24) and the patients who were diagnosed with molecular and immunological procedures (n = 54) did not show any statistical differences.

conclusionOur results indicate that radiotherapy-based treatment strategies for patients with POA-MALT lymphoma show a low rate of recurrence and may improve their prognosis even after the accurate diagnosis. However, contamination of the cases with reactive (polyclonal) lymphoid hyperplasia into those with MALT lymphoma should be carefully removed to avoid unnecessary treatment for malignancies that do not exist.

Indexed as

AdultAgedAged, 80 and overAntineoplastic AgentsEye NeoplasmsFemaleHumansImmunotherapyLymphoma, B-Cell, Marginal ZoneMaleMiddle AgedNeoplasm Recurrence, LocalRetrospective StudiesTreatment OutcomeAntineoplastic AgentsMonoclonalityNon-Hodgkin lymphomaPOA-MALT lymphomaRadiotherapyTreatment-associated mortality

Identifiers

PMID31172332

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.